Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting the Cumulative Live Birth Rate Further Ovarian Stimulation by Highly Purified Human Menotropin HP-hMG. A Multicentre, Retrospective Study

NCT04876300 is registered in ClinicalTrials.gov with Ferring Pharmaceuticals as lead sponsor.

NCT NCT04876300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04876300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting the Cumulative Live Birth Rate Further Ovarian Stimulation by Highly Purified Human Menotropin HP-hMG. A Multicentre, Retrospective Study
Lead sponsor
Ferring Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
November 4, 2021
Completion date
November 30, 2021
Enrollment
11,488 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

infertility, female